LifeMD Sees $220–230M 2026 Revenue While Flagging Q1 EBITDA Loss
LifeMD ended Q4 2025 with 322,000 active subscribers, $37 million cash, no debt and reported a GAAP net loss of $1.9 million despite strong revenue growth. 2026 guidance calls for $220–230 million revenue and $12–17 million adjusted EBITDA while anticipating a $4–5 million Q1 EBITDA loss from increased marketing spend.
1. Q4 2025 Performance
LifeMD closed Q4 with 322,000 active subscribers, strong revenue growth across care delivery, diagnostics and weight management, and launched the Oral Wegovy pill collaboration. The company processed approximately 20,000 prescriptions monthly through its newly licensed 50-state pharmacy network while reporting a $1.9 million GAAP net loss.
2. Balance Sheet and Operations
Entering 2026 with $37 million in cash, zero debt and the strongest balance sheet in its history, LifeMD is investing in AI and engineering to enhance patient operations, diagnostics and unit economics across its platform.
3. 2026 Financial Guidance
Full-year 2026 revenue is forecast at $220–230 million with adjusted EBITDA of $12–17 million. For Q1, management projects $48–49 million in revenue and an adjusted EBITDA loss of $4–5 million due to sales and marketing spend rising to $30 million.
4. Strategic Investments and Competition
Discretionary marketing investments and elevated patient acquisition costs in the GLP-1 weight loss business will pressure short-term profitability, while the women’s health segment is not expected to be EBITDA positive in its first year. Competition from Amazon and Lilly could affect market share.